The era of one size fits all medicine is giving way to a more precise approach, with new data showing that personalized treatments now represent more than a third of all new drug approvals. A new report reveals that in 2025, the U.S. Food and Drug Administration approved 16 new personalized medicines, which accounted for approximately 36% of all newly approved therapeutic molecular entities. This marks the sixth consecutive year that personalized medicines have made up more than one third of new approvals, cementing their role as a central pillar of modern healthcare.
The report highlights a major shift that has been building for over a decade. Fifteen years ago, personalized medicines represented less than ten percent of new drug approvals. Today, they are foundational. Among the 2025 milestones were the approval of five new gene and cell based therapies, along with significant advances in diagnostics, artificial intelligence, and rare disease innovation. These treatments are designed to target the specific genetic, biomarker, or molecular profile of a patient’s disease, moving away from broad, generalized therapies toward care that is tailored to the individual.
While oncology remains a leading area for these advances, the report notes that personalized approaches expanded in 2025 into neurological disorders, rare genetic diseases, immunologic conditions, hematologic cancers, ophthalmology, metabolic disorders, and Alzheimer’s disease. This broadening scope reflects a continued evolution toward biomarker driven and patient centered care across the entire medical spectrum. The report also documented steady growth in companion diagnostic approvals and authorizations, which help doctors identify which patients are most likely to benefit from a specific therapy.
What This Means for Patients and the Future of Medicine
For patients, these trends mean more treatment options that are safer and more effective because they are matched to the underlying biology of their disease. The report underscores that personalized medicine is no longer an emerging concept. It is now a central driver of biomedical innovation. However, continued progress will depend on sustained support for policies that encourage scientific innovation and ensure patient access to these advanced therapies.
Looking ahead, the Personalized Medicine Coalition will host its 20th annual conference in November 2026, bringing together leaders from across healthcare to discuss the future of the field. With personalized medicines now accounting for more than a third of new approvals and expanding into new disease areas, the trajectory points toward a future where treatment is increasingly precise, individualized, and effective for more patients than ever before.